There were 87 participants from 22 different countries at this Symposium. The various aspects on trophoblastic tumours discussed included pathology, genetics, epidemiology, immunology, endocrinology, monitoring and follow-up services, prognostic factors and therapy.
some patients, conception has not been followed by an identified pregnancy. It remains a possibility that during embryogenesis some cells differentiate to malignant trophoblast without the differentiation of other embryonic tissues; the so called "ab initio" choriocarcinoma.
Widespread dissemination of choriocarcinoma with apparent healing of the original primary in the uterus, leaving a scar or necrosis, probably occurs. There is now good evidence also that an abnormal trophoblast can persist following a molar pregnancy for many years, sometimes with an intervening normal pregnancy, before the abnormal trophoblast grows sufficiently to become clinially apparent. The rarity of involvement of the foetus by post-full-term choriocarcinoma suggests that the foetus is able to destroy the malignant isograft, since it is likely that at least some choriocarcinoma cells would enter the foetal circulation during the pregnancy.
Dr C. W. Elston (Nottingham) discussed the geographical distribution that has been recorded for hydatidiform moles, varying from 1/200 deliveries in the third world to 1/2000 deliveries in the United States. To avoid the bias of statistics taken purely from hospital confinements, he conducted a survey covering 87,350 deliveries in the Nottingham area between 1970 and 1978. There were 57 hydatidiform moles: an incidence of 1/1530 deliveries. Fifty of the moles showed complete hydropic change. The mean age of the patients was 25. Of the 48 that were available for follow-up for more than 1 year, one had required a hysterectomy and 3 had required chemotherapy, providing an overall complication rate of 8% Professor D. Attygalle (Sri Lanka) presented the results of a 10-year survey between 1969 and 1978 in Colombo, where they had seen 288 histologically confirmed gestational trophoblastic tumours during this period. The histological classification of these were hydatidiform mole in 233 (87.8%), invasive mole in 13 (4-5%) and choriocarcinoma in 22 (7-6%) All these tumours occurred in the Sinhalese, who form 75%O of the population. Hydatidiform moles occurred with diminishing frequency with increasing number of pregnancies, and was commoner in younger patients (20-29 years (g-HCG) and PSBG show good correlation.
There is a sub-set of patients in whom the PSBG remains high for substantial periods after the 3-HCG has returned to normal, but the significance of this remains uncertain. It had been noted that in some patients, the PSBG concentrations apparently rose at the time of administration of certain cytotoxic drugs, and this might relate to the release of intracellular PSBG during these courses of treatment.
Dr M. Seppala (Finland) presented results in 17 patients with choriocarcinoma, 8 with hydatidiform mole and 85 normal controls. In patients with trophoblastic tumours and raised HCG, the PSBG was also raised in 63%/. PSBG was also found in some patients with choriocarcinoma whose HCG values had become normal after treatment. 4.7% of the controls were also found to have high PSBG levels. PSBG measurements were thought to be an adjunct to HCG estimations in the management of patients with trophoblastic tumours.
Mr A. Kardana (London) discussed the current development at Charing Cross Hospital of an automated radioimmunoassay machine for measuring various antigens. This machine is capable of handling 5 different assays at different stages concurrently. At present, input dilution is the rate-limiting step, and up to 300 reactions are possible per hour. The application of this type of machine to increasing the facilities for patient monitoring for tumour markers was discussed.
Professor S. S. Dr D. P. Goldstein (U.S.A.) discussed the use of MTX with citrovorum factor in 61 patients with gestational trophoblastic tumours. MTX was used in a dose of 4 mg/kg and 6 mg/kg followed by citrovorum-factor rescue. The remission rates in non-metastatic and metastatic gestational trophoblastic tumours were 88 and 80% respectively. The higher dose of MTX did not reduce the need for subsequent treatment, but did increase the toxicity. If the HCG concentration did not fall by more than 1 log within 18 days, it was likely that the patient would require additional treatment.
Dr J. J. Fennelly (Ireland) discussed his results in treating 106 patients with gestational trophoblastic tumours over the last 15 years. Of 69 patients with hydatidiform mole, one died from septicaemia, while the other 68 are in complete remission. Of 21 patients with persistent trophoblastic activity, the majority resolved on MTX treatment, although 7 required hysterectomy. Sixteen patients were seen with choriocarcinoma, and 5 of these died. The deaths of all 5 were preventable in that they were patients who had had a hydatidiform mole and had not been adequately followed-up.
Dr C. E. Nystrom (Sweden) discussed the importance of distinguishing the treatment between invasive moles and pure choriocarcinoma. In addition to serial assays of HCG, he has also been monitoring serum diamine-oxidase levels which he has found useful in monitoring these patients. He has treated the invasive moles with MTX, whilst the patients with choriocarcinoma have received a multi-drug regime including vincristine, MTX, melphalan and actinomycin D.
Professor Ho-Kei Ma (Hong Kong) reviewed the results of 85 patients treated between 1972 and 1978. The patients have been divided into low and high-risk groups on the basis of: (1) Professor Bagshawe (London) reviewed some of the points that had been raised in discussion earlier in the meeting. At present, the current recommendation for patients who have had a hydatidiform mole is that their HCG concentration should be normal for at least 6 months before the patient has a further pregnancy. Patients who have had a mole should be followed up for 2 years, as occasionally (one in 500 cases) there has been a recurrence after the HCG has fallen to the normal range. The development of the schedules using MTX and folinic acid have resulted in a greater safety margin when the patient receives folinic acid, than with MTX alone. At present, there is no evidence that, where a trophoblastic tumour is resistant to low-dose MTX, increasing the dose produces a better response. In the Charing Cross series, where more than 90% of the 500 patients have been followed-up for between 1 and 20 years, so far there have only been 2 second tumours (one carcinoma of the cervix, and one acute myeloid leukaemia). CNS involvement at the onset of therapy is not necessarily disastrous. In a fair proportion of patients, the tumour can be eliminated even in this site with a combination of systemic therapy and intrathecal MTX. High-dose systemic MTX (3 g/m2) can produce what is probably a therapeutic concentration (> 10-6M) of MTX in the CSF at the end of the 24h infusion. The role of this approach in therapy has yet to be finalized. Overall, there has been a progressive improvement in the survival of the patients since the introduction of chemotherapy, and at present the current survival rate in the Charing Cross Series is 94%.
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